Risks
3 risks
Risk Intelligence
Cenexi turnaround delays
View Risks →Gland Pharma Limited — Q4 FY24
Gland Pharma reported a strong Q4 FY24 with consolidated revenue of INR 16,375 million (+19% YoY) and EBITDA of INR 3,587 million (+113% YoY), driven by a robust recovery in the base business (revenue +50% YoY, EBITDA margin 37%).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Gland Pharma reported a strong Q4 FY24 with consolidated revenue of INR 16,375 million (+19% YoY) and EBITDA of INR 3,587 million (+113% YoY), driven by a robust recovery in the base business (revenue +50% YoY, EBITDA margin 37%). The Cenexi acquisition contributed INR 3,637 million revenue but posted negative EBITDA of INR 720 million due to operational disruptions and a EUR 20-25 million order backlog. Management guided for base business growth of 14-15% annually and expects Cenexi to reach high-teen EBITDA margins in 1-2 years via capacity expansion and tech transfers. Key risks include slower-than-expected Cenexi turnaround and potential pricing pressure in the US generics market.
ग्लैंड फार्मा ने चौथी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई 1,637 करोड़ रुपये रही, जो पिछले साल से 19% ज्यादा है। मुनाफा (EBITDA) 359 करोड़ रुपये रहा, जो 113% बढ़ा। इसकी वजह मुख्य कारोबार में मजबूत सुधार है, जिसमें कमाई 50% बढ़ी और मुनाफा मार्जिन 37% रहा। Cenexi कंपनी ने 364 करोड़ रुपये की कमाई दी, लेकिन परिचालन समस्याओं के कारण 72 करोड़ रुपये का नुकसान हुआ। प्रबंधन को उम्मीद है कि मुख्य कारोबार हर साल 14-15% बढ़ेगा और Cenexi 1-2 साल में अच्छा मुनाफा देने लगेगा। जोखिमों में Cenexi का धीमा सुधार और अमेरिकी बाजार में कीमतों पर दबाव शामिल है।
Risks3 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Base Business EBITDA Margin
37%
+1600bps YoY
Base business (ex-Cenexi) EBITDA margin improved to 37% in Q4 FY24 from 21% in Q4 FY23.
Cenexi Order Backlog
EUR 20-25M
N/A
Cenexi has an order backlog of EUR 20-25 million due to capacity constraints.
ANDAs Filed (FY24)
19
N/A
Gland filed 19 ANDAs in FY24, with 24 approvals received.
Eribulin Market Size
$170-180M
N/A
Eribulin, a complex injectable launched in Q4, addresses a market size of $170-180 million.
What Changed vs Last Quarter
NEW
Cenexi to reach high-teen EBITDA margins in 1-2 years
Cenexi targets high-teen EBITDA margins within 1-2 years through operational fixes, tech transfers, and capacity expansion.
NEW
Cenexi quarterly revenue to ramp to EUR 50M in ~3 quarters
Cenexi's quarterly revenue is expected to gradually increase from EUR 40M to EUR 50M in about three quarters.
UPDATED
Base business annual growth of 14-15%
Management expects the base business (ex-Cenexi) to grow at 14-15% annually, driven by new launches and market share gains.
DROPPED
Cenexi EBITDA breakeven in 12-15 months
Management expects Cenexi to achieve EBITDA breakeven within 12-15 months, with medium-term EBITDA margin target of 10%.
DROPPED
Cenexi incremental revenue of EUR 30-40 million by FY2026
New programs in tech transfer and approval stages are expected to add EUR 30-40 million to Cenexi's annual revenue in the medium term.
DROPPED
Cenexi CapEx of EUR 30 million
Cenexi will invest approximately EUR 30 million in new equipment and capacity expansion over the next year.
NEW RISK
Pricing pressure in US generics
While pricing has stabilized, any resurgence of price erosion could impact base business margins.
NEW RISK
Slow progress in biologics and China
Biologics CDMO and China market progress have been slower than anticipated, with no near-term material contribution expected.
RISK GONE
Cenexi revenue growth may be pushed out
Analyst question highlighted that operational issues could delay the EUR 30-40 million incremental revenue from new programs beyond FY2026.
RISK GONE
India business decline
India revenue declined 7% YoY and remains a low-focus market, with limited growth visibility due to DPCO pricing pressures.
🤫 Topics management stopped discussing
Mentioned in Q2 FY24, Q3 FY24
Ex-Cenexi business targets mid-teens revenue growth over the next 2-3 years, driven by US complex products and CDMO opportunities.
Mentioned in Q1 FY24, Q2 FY24
Cenexi's annual summer shutdown (4 weeks in France, 3 in Belgium) will continue to cause revenue loss and negative EBITDA in Q2 each year.
Mentioned in Q2 FY24, Q3 FY24
New programs in tech transfer and approval stages are expected to add EUR 30-40 million to Cenexi's annual revenue in the medium term.
Mentioned in Q1 FY24, Q2 FY24
Management declined to provide a timeline for Cenexi reaching 13-15% EBITDA margins, citing early stage of integration.
Mentioned in Q1 FY24, Q2 FY24
Management expects steady quarter-on-quarter growth in the base business, driven by new launches and volume expansion.
Fast read
Guidance and risk preview
Management expects the base business (ex-Cenexi) to grow at 14-15% annually, driven by new launches and market share gains.
Cenexi's operational issues and capacity constraints may delay profitability, with management acknowledging a few quarters delay.
View Risks →